The FDA has set a Prescription Drug User Fee Act action date for 24 May 2026.

The FDA has accepted for review the sBLA for subcutaneous lecanemab-irmb as a weekly starting dose for Alzheimer disease.

LEQEMBI is currently approved in 53 countries and regions and is under regulatory review in 7 countries. In August 2025, the US FDA approved LEQEMBI IQLIK 360 mg for weekly subcutaneous maintenance ...

A major storm system is set to bring "potentially catastrophic" winter weather across the southern U.S. this weekend, ...

Blacksmith Medicines, Inc. (Blacksmith), a leading biopharma dedicated to discovering and developing therapeutics targeting metalloenzymes, today announced that data on its lead antibacterial ...

Even as NASA celebrated the rollout of the Space Launch System rocket and Orion spacecraft for Artemis II over the weekend, ...

Gonzalez told the Miami Herald he wants to “return to public service to stabilize the city’s finances and bring experience to ...

Organizations such as trustees’ offices in Tippecanoe County, Lafayette Urban Ministry and the Area IV Agency on Aging and ...

A striking feature of US-China trade tensions in mid-2025 is China’s acceleration of exports to the US ahead of new tariff ...

At the frontlines of the drug crisis, Marck Rivera and his group of volunteer EMTs practice harm-reduction in the streets of ...

While many commenters say that 2025 ushered in a new era for the SEC’s regulation of the digital asset industry, the SEC’s ...

US billionaires got $1.5T richer in Trump's first year. The wealth of the 15 richest US centi-billionaires surged 33%.